Advertisement

Topics

Alchemie Limited Company Profile

15:01 EDT 19th September 2017 | BioPortfolio

Alchemia has become internationally recognised for its unique platform technology for the production of complex sugar-based molecules called oligosaccharides.

Oligosaccharides play pivotal roles in many disease processes. For example, many diarrhoea-causing organisms use these sugar-based molecules to attach themselves to the gut wall. Administration of similar sugars has been shown in some cases to prevent these disorders.



Sugar-based molecules on the surface of cancer cells can also be responsible for their ability to attach to other organs around the body (metastases). Several companies have oligosaccharides in clinical trials, which aim to prevent the spread of certain cancers.



Despite the clinical need for these molecules, they have been very difficult to manufacture cost effectively, if at all, since sugars can combine together in many ways to produce complex mixtures which are useless for clinical research.



Alchemia has developed and patented unique chemistry that for the first time allows these molecules to be produced cost effectively and in sufficient amounts to undertake clinical studies.

Location

Australia


News Articles [15 Associated News Articles listed on BioPortfolio]

Quotient Limited to Participate in the UBS Global Healthcare Conference

JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte. Li...

Quotient Limited to Participate in the Jefferies 2017 Global Healthcare Conference

JERSEY, Channel Islands, May 31, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

Quotient Limited to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

JERSEY, Channel Islands, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive...

Kevin McCann and Mark Nelson Appointed to the Board of Directors of Telix Pharmaceuticals Limited

MELBOURNE, Australia, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) is pleased to announce that Mr. Kevin McCann AM and Dr. Mark Nelson have be...

Quotient Limited to Report Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call

JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and ...

Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results

Initial MosaiQ manufacturing system commissioned and validatedFirst “commercially ready” MosaiQ Instrument delivered to QuotientInternal validation of MosaiQ underway, with EU field trials expe...

Quotient Limited Reports Results From Latest MosaiQ Performance Evaluation Studies Prior to Commencing Verification and Validation Studies

Performance evaluation studies confirm required concordance levels for all assaysVerification and validation studies to commence shortly European field trials still expected to be completed in CY17...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [82 Associated Companies listed on BioPortfolio]

AARTI INDUSTRIES LIMITED

The first unit of AARTI group, ALCHEMIE LABORATORIES, commenced commercial production of DIMETHYL SULPHATE (DMS) in the year 1975. Today, AARTI has acquired world-class expertise in the development an...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

VASUDHA PHARMA CHEM LIMITED

VASUDHA PHARMA CHEM LIMITED (VPCL) is a Company promoted by a team of accomplished technocrats for Bulk Drug industry with a total capital of Rupees 153 million ( US $ 5Million).All the promoters of V...

More Information about "Alchemie Limited" on BioPortfolio

We have published hundreds of Alchemie Limited news stories on BioPortfolio along with dozens of Alchemie Limited Clinical Trials and PubMed Articles about Alchemie Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alchemie Limited Companies in our database. You can also find out about relevant Alchemie Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Clostridium difficile (CDI)
A clostridium difficile infection (CDI) is a type of bacterial infection that can affect the digestive system. It most commonly affects people who are staying in hospital.  The symptoms of CDI can range from mild to severe and include: diarrhoe...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record